A project spearheaded by a researcher at the University of Ottawa's Faculty of Medicine has been awarded $9 million in Canadian Institutes of Health Research (CIHR) funding to create a national network for better researching and responding to the global threat COVID-19 variants pose.
Led by Dr. Marc-Andre Langlois, the Coronavirus Variants Rapid Response Network or CoVaRR-Net, will enable the real-time assessment of both the immune response to the virus variants and whether these variants are resistant to existing vaccines. The findings will provide decision makers with guidance regarding drug therapy, vaccine effectiveness, and other public health strategies.
"CoVaRR-Net is poised to contribute to the Canadian effort to mitigate the impact of harmful variants of concern (VOC) on citizens of Canada and on the world population. This project constitutes a harmonized and rapid approach for real time assessment of the possible threat of SARS-CoV-2 variants and will serve as a blueprint for future pandemics to safeguard the health of all Canadians," says Dr. Langlois, who is the Canada Research Chair in Molecular Virology and Intrinsic Immunity and Full Professor in the Department of Biochemistry, Microbiology, and Immunology at the University of Ottawa. "This network will act as Canada's integrated platform for determining how VOCs impact Canadians from diverse communities and demographics and for tracking how SARS-CoV-2 is mutating in real time."
Dr. Langlois and his team will collaborate with the Public Health Agency of Canada's National Microbiology Lab (NML), the Canadian COVID-19 Genomics Network (CanCOGeN), provincial and territorial public health labs, and other national and international bodies.
The project is supported by various uOttawa partners, including:
CoVaRR-Net members and research partners include:
###